Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update


Crinetics Pharmaceuticals reported financial results and provided an update on third quarter 2023 progress

Crinetics Announces October 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 619,100 shares of its common stock to eleven new non-executive employees

Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023


Crinetics management will participate in a fireside chat and conduct investor meetings at the Cantor Global Healthcare Conference on September 26, 2023

Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock


Crinetics intends to use the net proceeds from the offering to fund the development of paltusotine, CRN04894 and its other research and development programs, and for working capital and general corporate purposes.

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock


Crinetics announced today that it intends to offer and sell, subject to market and other conditions, $250.0 million of shares of its common stock in an underwritten public offering.